Vonoprazan Therapy in Gastroesophageal Reflux Disease (GERD): Effects on the Severity and Frequency of GERD in Relation to Hiatus Hernia
Abstract
Objective This study aimed to assess vonoprazan’s effectiveness in reducing the severity and frequency of gastroesophageal reflux disease (GERD) symptoms in relation to hiatus hernia. Methods This prospective single-arm cohort study (before and after treatment) was conducted at Hayatabad Medical Complex, Peshawar, from January 1, 2025, to August 31, 2025. It enrolled 110 patients with GERD, based on clinical evaluation and endoscopic confirmation to exclude other pathologies and evaluate for the presence of hiatus hernia. Inclusion criteria included patients aged 18-65 years presenting with typical GERD symptoms, such as heartburn or regurgitation. Patients were excluded if they had a history of gastrointestinal surgery, esophageal malignancy, pregnancy, lactation, and significant hepatic or renal impairment or were on concurrent acid-suppressive medications. All patients were given 20 mg vonoprazan monotherapy for four weeks. Symptom severity and frequency were assessed pre- and post-treatment using a validated structured questionnaire. Clinical response evaluation and subgroup analysis were performed to evaluate treatment outcomes in patients with and without hiatus hernia. Results The total number of patients was 110, with a mean age of 43.65 ± 9.90 years and a mean BMI of 26.81 ± 2.76. Before treatment, 33 (30.0%) had severe symptoms, and 58 (52.7%) reported symptoms more than four times per week. Following treatment, 97 (88.2%) reported complete symptom resolution, and…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 110 participants or records.
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.